ADT + Abiraterone versus ADT + Docetaxel

Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology explains which combination improved survival for patients with prostate cancer: androgen deprivation therapy plus abiratero... Author: ASCO2017 Added: 06/15/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts